Expansion Into Renal Pharmaceuticals

• $7+ billion market

• Leverages Baxter channel to nephrologists and patients

• Focused on three therapeutic areas:

  • Managing uremic and dialysis-related complications
  • Preventing or delaying disease progression
  • Treating diseases of the kidney

• 12 active business development projects

Previous slide

Next slide

Back to first slide

View graphic version